Sp795
MOLECULAR CYST FLUID ANALYSIS IS THE WAY TO GO FOR RISK STRATIFICATION OF IPMNS
Date
May 20, 2024
Presenter
Tracks
Related Products
INCORPORATING NEXT-GENERATION SEQUENCING IN THE MANAGEMENT ALGORITHM OF PANCREATIC CYSTS
BACKGROUND: Pancreatic cancer (PC) features highly proliferative cancer cells and a dense stroma modulating tumor growth. Due to the invasive behavior of PC and the lack of effective treatments, there is a pressing need to develop therapies targeted at tumorigenic events to slow down PC progression…
A PROSPECTIVE, MULTI-INSTITUTIONAL STUDY REVEALS THE COMBINATION OF RNA ANALYSIS WITH DNA-BASED NEXT-GENERATION SEQUENCING (NGS) IMPROVES THE PREOPERATIVE CLASSIFICATION OF PANCREATIC CYSTS AND IDENTIFICATION OF ADVANCED NEOPLASIA
BACKGROUND: As outlined by the Kyoto guidelines, targeted DNA-based NGS of pancreatic cyst fluid (PCF) is an important adjunct to the evaluation of pancreatic cyst patients…
CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING FOR DIFFERENTIATING MAIN-DUCT INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM AND CHRONIC PANCREATITIS AS ETIOLOGY OF PANCREATIC DUCT DILATION
The management of pancreatic duct (PD) dilation is challenging as it may be secondary to both benign and malignant conditions…
MULTI-CENTER BLINDED VALIDATION OF THE DIAGNOSTIC UTILITY OF CYST GLUCOSE AND AMPHIREGULIN TO DIFFERENTIATE MUCINOUS FROM NON-MUCINOUS PANCREATIC CYSTS.
BACKGROUND AND AIMS: Currently, most patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMN) are offered indefinite surveillance, resulting in health care costs with questionable benefits regarding cancer prevention…
